EMIT II Plus Amphetamines AssayOptimize Precision for Amphetamine Testing

The EMIT® II Plus Amphetamines Assay is intended for the qualit ative and semiquantitative determination of amphetamines in human urine, at a cutoff value of 300 ng/mL, 500 ng/mL, or 1000 ng/mL. The SAMHSA initial test cutoff level is 500 ng/mL.

Contact Us

Features & Benefits

Amphetamine, dextroamphetamine, and methamphetamine are collectively referred to as amphetamines. Today, amphetamine is used as an aid in treating narcolepsy, some forms of depression, and Attention Deficit Hyperactivity Disorder (ADHD). Yet, due to its potential for abuse or addiction, other treatment methods are used more frequently.

  • Highly specific with minimal cross-reactivity to common over-the-counter cold medicines
  • Minimal cross-reactivity to commonly prescribed medications often used to treat obesity and narcolepsy
  • Excellent precision—all Within-Lab (Total) CVs ≤ 0.7% or less across the assay range
  • >96% correlation at the 500 ng/mL cutoff with reference method (GC/MS)
  • Equivalency for d-meth and d-amph at both the 300 and 500 cutoff levels
  • Optimized assay performance at the cutoff levels for zero overlap
  • Triple cutoff available with one assay


Applications available for the Viva-Jr®, Viva-E®, V-Twin®, and AU® Series analyzers*

Technical Specifications

 Assay Principle

  Homogeneous Enzyme Multiplied Immonoassay (EMIT)


  300 ng/mL, 500 ng/mL, and 1000 ng/mL



 Reagent Stability

  Unopened until expiration date. On-board instrument up to: 4 weeks

 Calibration Frequency

  As indicated by control results